BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling

eLife

Volumn 2013, Issue 2, 2013, Pages

  Vin, Harina ^a   Ojeda, Sandra S ^a   Ching, Grace ^a   Leung, Marco L ^a,b   Chitsazzadeh, Vida ^a,b   Dwyer, David W ^a   Adelmann, Charles H ^a   Restrepo, Monica ^a   Richards, Kristen N ^a,c   Stewart, Larissa R ^a,c   Du, Lili ^a   Ferguson, Scarlett B ^d   Chakravarti, Deepavali ^a,b   Ehrenreiter, Karin ^e   Baccarini, Manuela ^e   Ruggieri, Rosamaria ^f   Curry, Jonathan L ^a   Kim, Kevin B ^a   Ciurea, Ana M ^c   Duvic, Madeleine ^b,c   Prieto, Victor G ^a   Ullrich, Stephen E ^a,b   Dalby, Kevin N ^d   Flores, Elsa R ^a,b   Tsai, Kenneth Y ^a,b,c   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c University of Texas Health Science Center at Houston   (United States)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^e MAX F PERUTZ LABORATORIES   (Austria)

^f FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; BRAF PROTEIN, HUMAN; CASPASE 3; DABRAFENIB; DOXORUBICIN; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; LENTIVIRUS VECTOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE P38; N [3 (5 CHLORO 1H PYRROLO [2, 3 B] PYRIDINE 3 CARBONYL) 2, 4 DIFLUOROPHENYL] PROPANESULFONAMIDE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; OXIME; PHARMACOLOGY; SELUMETINIB; STRESS ACTIVATED PROTEIN KINASE; SULFONAMIDE; UNCLASSIFIED DRUG; VEMURAFENIB;

ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTAGONISTS AND INHIBITORS; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECTS; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HAIRLESS MOUSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MALE; METABOLISM; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; ULTRAVIOLET IRRADIATION; WESTERN BLOTTING;

ANIMALS; ANTAGONISTS AND INHIBITORS; APOPTOSIS; DRUG EFFECTS; HUMANS; IMIDAZOLES; INDOLES; MAP KINASE KINASE 4; METABOLISM; MICE; MICE, HAIRLESS; OXIMES; PHARMACOLOGY; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION; SULFONAMIDES;

MURINAE; MUS;

EID: 84887397131     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.00969.001     Document Type: Article

References (71)

1. Abe S, Yagi T, Ishiyama S, Hiroe M, Marumo F, Ikawa Y. 1995. Molecular cloning of a novel serine/threonine kinase, MRK, possibly involved in cardiac development. Oncogene 11:2187-95.
2. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. 2011. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol 29:1039-45. doi: 10.1038/nbt.2017.
3. Bloem LJ, Pickard TR, Acton S, Donoghue M, Beavis RC, Knierman MD, et al. 2001. Tissue distribution and functional expression of a cDNA encoding a novel mixed lineage kinase. J Mol Cell Cardiol 33:1739-50. doi: 10.1006/jmcc.2001.1437.
4. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. 2010. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596-9. doi: 10.1038/nature09454.
5. Brennan DF, Dar AC, Hertz NT, Chao WC, Burlingame AL, Shokat KM, et al. 2011. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature 472:366-9. doi: 10.1038/nature09860.
6. Brown K, Buchmann A, Balmain A. 1990. Carcinogen-induced mutations in the mouse c-Ha-ras gene provide evidence of multiple pathways for tumor progression. Proc Natl Acad Sci USA 87:538-42. doi: 10.1073/pnas.87.2.538.
7. Cellurale C, Weston CR, Reilly J, Garlick DS, Jerry DJ, Sluss HK, et al. 2010. Role of JNK in a Trp53-dependent mouse model of breast cancer. PLOS ONE 5:e12469. doi: 10.1371/journal.pone.0012469.
8. Cellurale C, Sabio G, Kennedy NJ, Das M, Barlow M, Sandy P, et al. 2011. Requirement of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation. Mol Cell Biol 31:1565-76. doi: 10.1128/MCB.01122-10.
9. Cellurale C, Girnius N, Jiang F, Cavanagh-Kyros J, Lu S, Garlick DS, et al. 2012. Role of JNK in mammary gland development and breast cancer. Cancer Res 72:472-81. doi: 10.1158/0008-5472.CAN-11-1628.
10. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-16. doi: 10.1056/NEJMoa1103782.
11. Chen YR, Wang X, Templeton D, Davis RJ, Tan TH. 1996. The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. J Biol Chem 271:31929-36. doi: 10.1074/jbc.271.50.31929.
12. Chen N, Nomura M, She QB, Ma WY, Bode AM, Wang L, et al. 2001. Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice. Cancer Res 61:3908-12.
13. Cheng YC, Kuo WW, Wu HC, Lai TY, Wu CH, Hwang JM, et al. 2009. ZAK induces MMP-2 activity via JNK/p38 signals and reduces MMP-9 activity by increasing TIMP-1/2 expression in H9c2 cardiomyoblast cells. Mol Cell Biochem 325:69-77. doi: 10.1007/s11010-008-0021-1.
14. Cho YY, Bode AM, Mizuno H, Choi BY, Choi HS, Dong Z. 2004. A novel role for mixed-lineage kinase-like mitogen-activated protein triple kinase alpha in neoplastic cell transformation and tumor development. Cancer Res 64:3855-64. doi: 10.1158/0008-5472.CAN-04-0201.
15. Cho KJ, Kasai RS, Park JH, Chigurupati S, Heidorn SJ, van der Hoeven D, et al. 2012. Raf inhibitors target ras spatiotemporal dynamics. Curr Biol 22:945-55. doi: 10.1016/j.cub.2012.03.067.
16. Collins NL, Reginato MJ, Paulus JK, Sgroi DC, Labaer J, Brugge JS. 2005. G1/S cell cycle arrest provides anoikis resistance through Erk-mediated Bim suppression. Mol Cell Biol 25:5282-91. doi: 10.1128/MCB.25.12.5282-5291.2005.
17. Das M, Garlick DS, Greiner DL, Davis RJ. 2011. The role of JNK in the development of hepatocellular carcinoma. Genes Dev 25:634-45. doi: 10.1101/gad.1989311.
18. Daub H, Specht K, Ullrich A. 2004. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov 3:1001-10. doi: 10.1038/nrd1579.
19. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, et al. 2011. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 29:1046-51. doi: 10.1038/nbt.1990.
20. Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, et al. 1994. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76:1025-37. doi: 10.1016/0092-8674(94)90380-8.
21. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, et al. 2012. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379:1893-901. doi: 10.1016/S0140-6736(12)60398-5.
22. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. 2010. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-19. doi: 10.1056/NEJMoa1002011.
23. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. 2012. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. N Engl J Med 367:1694-703. doi: 10.1056/NEJMoa1210093.
24. Gowrishankar K, Snoyman S, Pupo GM, Becker TM, Kefford RF, Rizos H. 2012. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition. J Invest Dermatol 132:1850-9. doi: 10.1038/jid.2012.63.
25. Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN, et al. 2012. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 11:909-20. doi: 10.1158/1535-7163.MCT-11-0989.
26. Gross EA, Callow MG, Waldbaum L, Thomas S, Ruggieri R. 2002. MRK a mixed lineage kinase-related molecule that plays a role in gamma-radiation-induced cell cycle arrest. J Biol Chem 277:13873-82. doi: 10.1074/jbc.M111994200.
27. Haeusgen W, Herdegen T, Waetzig V. 2011. The bottleneck of JNK signaling: molecular and functional characteristics of MKK4 and MKK7. Eur J Cell Biol 90:536-44. doi: 10.1016/j.ejcb.2010.11.008.
28. Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, et al. 2010. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 23:190-200. doi: 10.1111/j.1755-148X.2010.00685.x.
29. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:646-74. doi: 10.1016/j.cell.2011.02.013.
30. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. 2010. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464:431-5. doi: 10.1038/nature08833.
31. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. 2012. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-65. doi: 10.1016/S0140-6736(12)60868-X.
32. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. 2010. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140:209-21. doi: 10.1016/j.cell.2009.12.040.
33. Hildesheim J, Awwad RT, Fornace AJ Jnr. 2004. p38 Mitogen-activated protein kinase inhibitor protects the epidermis against the acute damaging effects of ultraviolet irradiation by blocking apoptosis and inflammatory responses. J Invest Dermatol 122:497-502. doi: 10.1111/j.1523-1747.2004.22229.x.
34. Hu J, Yu H, Kornev AP, Zhao J, Filbert EL, Taylor SS, et al. 2011. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF. Proc Natl Acad Sci USA 108:6067-72. doi: 10.1073/pnas.1102554108.
35. Huang CY, Chueh PJ, Tseng CT, Liu KY, Tsai HY, Kuo WW, et al. 2004. ZAK re-programs atrial natriuretic factor expression and induces hypertrophic growth in H9c2 cardiomyoblast cells. Biochem Biophys Res Commun 324:973-80. doi: 10.1016/j.bbrc.2004.09.156.
36. Hubner A, Mulholland DJ, Standen CL, Karasarides M, Cavanagh-Kyros J, Barrett T, et al. 2012. JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proc Natl Acad Sci USA 109:12046-51. doi: 10.1073/pnas.1209660109.
37. Jandhyala DM, Ahluwalia A, Obrig T, Thorpe CM. 2008. ZAK: a MAP3Kinase that transduces Shiga toxin-and ricin-induced proinflammatory cytokine expression. Cell Microbiol 10:1468-77. doi: 10.1111/j.1462-5822.2008.01139.x.
38. Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M. 2005. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120:649-61. doi: 10.1016/j.cell.2004.12.041.
39. Karreth FA, DeNicola GM, Winter SP, Tuveson DA. 2009. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). Mol Cell 36:477-86. doi: 10.1016/j.molcel.2009.10.017.
40. Keshet Y, Seger R. 2010. The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions. Methods Mol Biol 661:3-38. doi: 10.1007/978-1-60761-795-2_1.
41. Lehman TA, Modali R, Boukamp P, Stanek J, Bennett WP, Welsh JA, et al. 1993. p53 mutations in human immortalized epithelial cell lines. Carcinogenesis 14:833-9. doi: 10.1093/carcin/14.5.833.
42. Liu TC, Huang CJ, Chu YC, Wei CC, Chou CC, Chou MY, et al. 2000. Cloning and expression of ZAK, a mixed lineage kinase-like protein containing a leucine-zipper and a sterile-alpha motif. Biochem Biophys Res Commun 274:811-6. doi: 10.1006/bbrc.2000.3236.
43. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. 2012. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13:1087-95. doi: 10.1016/S1470-2045(12)70431-X.
44. McKay MM, Ritt DA, Morrison DK. 2011. RAF inhibitor-induced KSR1/B-RAF binding and its effects on ERK cascade signaling. Curr Biol 21:563-8. doi: 10.1016/j.cub.2011.02.033.
45. Menzies AM, Kefford RF, Long GV. 2013. Paradoxical oncogenesis: are all BRAF inhibitors equal? Pigment Cell Melanoma Res 26:611-5. doi: 10.1111/pcmr.12132.
46. Miyata Y, Akashi M, Nishida E. 1999. Molecular cloning and characterization of a novel member of the MAP kinase superfamily. Genes Cells 4:299-309. doi: 10.1046/j.1365-2443.1999.00261.x.
47. Naik E, Michalak EM, Villunger A, Adams JM, Strasser A. 2007. Ultraviolet radiation triggers apoptosis of fibroblasts and skin keratinocytes mainly via the BH3-only protein Noxa. J Cell Biol 176:415-24. doi: 10.1083/jcb.200608070.
48. Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, Jones R, et al. 2011. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 30:316-21. doi: 10.1200/JCO.2011.36.7680.
49. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, et al. 2000. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288:1053-8. doi: 10.1126/science.288.5468.1053.
50. Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen A, Munko AC, et al. 2011. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 71:2750-60. doi: 10.1158/0008-5472.CAN-10-2954.
51. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. 2010. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464:427-30. doi: 10.1038/nature08902.
52. Sauter KA, Magun EA, Iordanov MS, Magun BE. 2010. ZAK is required for doxorubicin, a novel ribotoxic stressor, to induce SAPK activation and apoptosis in HaCaT cells. Cancer Biol Ther 10:258-66. doi: 10.4161/cbt.10.3.12367.
53. She QB, Chen N, Bode AM, Flavell RA, Dong Z. 2002. Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 62:1343-8.
54. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. 2012. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707-14. doi: 10.1056/NEJMoa1112302.
55. Stone SM, Thorpe CM, Ahluwalia A, Rogers AB, Obata F, Vozenilek A, et al. 2012. Shiga toxin 2-induced intestinal pathology in infant rabbits is A-subunit dependent and responsive to the tyrosine kinase and potential ZAK inhibitor imatinib. Front Cell Infect Microbiol 2:135. doi: 10.3389/fcimb.2012.00135.
56. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, et al. 2004. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA 101:6062-7. doi: 10.1073/pnas.0400782101.
57. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al. 2012. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366:207-15. doi: 10.1056/NEJMoa1105358.
58. Su X, Zhu CL, Shi W, Ni LC, Shen JH, Chen J. 2012. Transient global cerebral ischemia induces up-regulation of MLTKalpha in hippocampal CA1 neurons. J Molecular Histol 43:187-93. doi: 10.1007/s10735-011-9381-z.
59. Tobiume K, Matsuzawa A, Takahashi T, Nishitoh H, Morita K, Takeda K, et al. 2001. ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep 2:222-8. doi: 10.1093/embo-reports/kve046.
60. Tosti E, Waldbaum L, Warshaw G, Gross EA, Ruggieri R. 2004. The stress kinase MRK contributes to regulation of DNA damage checkpoints through a p38gamma-independent pathway. J Biol Chem 279:47652-60. doi: 10.1074/jbc.M409961200.
61. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, et al. 2000. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 288:870-4. doi: 10.1126/science.288.5467.870.
62. Tournier C, Dong C, Turner TK, Jones SN, Flavell RA, Davis RJ. 2001. MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines. Genes Dev 15:1419-26. doi: 10.1101/gad.888501.
63. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, et al. 2008. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 105:3041-6. doi: 10.1073/pnas.0711741105.
64. van Kranen HJ, de Gruijl FR, de Vries A, Sontag Y, Wester PW, Senden HC, et al. 1995. Frequent p53 alterations but low incidence of ras mutations in UV-B-induced skin tumors of hairless mice. Carcinogenesis 16:1141-7. doi: 10.1093/carcin/16.5.1141.
65. Vanan I, Dong Z, Tosti E, Warshaw G, Symons M, Ruggieri R. 2012. Role of a DNA damage checkpoint pathway in ionizing radiation-induced glioblastoma cell migration and invasion. Cell Mol Neurobiol 32:1199-208. doi: 10.1007/s10571-012-9846-y.
66. Ventura JJ, Hubner A, Zhang C, Flavell RA, Shokat KM, Davis RJ. 2006. Chemical genetic analysis of the time course of signal transduction by JNK. Mol Cell 21:701-10. doi: 10.1016/j.molcel.2006.01.018.
67. Wang X, Mader MM, Toth JE, Yu X, Jin N, Campbell RM, et al. 2005. Complete inhibition of anisomycin and UV radiation but not cytokine induced JNK and p38 activation by an aryl-substituted dihydropyrrolopyrazole quinoline and mixed lineage kinase 7 small interfering RNA. J Biol Chem 280:19298-305. doi: 10.1074/jbc.M413059200.
68. Weston CR, Wong A, Hall JP, Goad ME, Flavell RA, Davis RJ. 2004. The c-Jun NH2-terminal kinase is essential for epidermal growth factor expression during epidermal morphogenesis. Proc Natl Acad Sci USA 101:14114-9. doi: 10.1073/pnas.0406061101.
69. Whittaker S, Kirk R, Hayward R, Zambon A, Viros A, Cantarino N, et al. 2010. Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Sci Transl Med 2:35ra41. doi: 10.1126/scitranslmed.3000758.
70. Wong J, Smith LB, Magun EA, Engstrom T, Kelley-Howard K, Jandhyala DM, et al. 2013. Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of doxorubicin. Cancer Biol Ther 14:56-63. doi: 10.4161/cbt.22628.
71. Yang JJ, Lee YJ, Hung HH, Tseng WP, Tu CC, Lee H, et al. 2010. ZAK inhibits human lung cancer cell growth via ERK and JNK activation in an AP-1-dependent manner. Cancer Sci 101:1374-81. doi: 10.1111/j.1349-7006.2010.01537.x.